New insights into pediatric POTS: tailored therapies improve outcomes
en-GBde-DEes-ESfr-FR

New insights into pediatric POTS: tailored therapies improve outcomes

10/03/2025 TranSpread

Postural orthostatic tachycardia syndrome (POTS) is a form of chronic orthostatic intolerance that primarily affects children and adolescents, leading to debilitating symptoms like lightheadedness, blurred vision, and fatigue upon standing. Unfortunately, the condition is often misunderstood and misdiagnosed, complicating its management. While current treatments range from physical therapies to pharmacological options, their effectiveness can vary significantly between patients. The lack of a standardized treatment approach, combined with the complex nature of the condition, has made it difficult to predict which therapies will work best for each individual. Given these challenges, there is an urgent need for more personalized treatment strategies based on a deeper understanding of POTS’ underlying mechanisms.

Published (DOI: 10.1002/pdi3.2509) in Pediatric Discovery on November 24, 2024, a comprehensive review led by researchers from Peking University First Hospital explores these mechanisms and presents individualized management strategies for pediatric POTS. The review emphasizes the importance of identifying key physiological and biochemical markers, such as central hypovolemia and hyperadrenergic states, which can guide clinicians in choosing the most effective treatments for each patient.

The study explores a range of treatment options, including physical therapies like exercise training and orthostatic maneuvers, which have shown promise in improving autonomic function. However, not all patients respond equally, highlighting the need for a tailored approach. For example, biomarkers such as baroreflex sensitivity (BRS) and 24-hour urinary sodium levels have been identified as valuable predictors of a patient’s response to oral rehydration salts (ORS). Similarly, heart rate changes during head-up tilt tests (HUTT) and plasma norepinephrine levels can help guide the use of β-blockers like metoprolol. The review also highlights the role of α-adrenergic agonists, such as midodrine hydrochloride, for patients with peripheral vascular dysfunction, with biomarkers like midregional pro-adrenomedullin (MR-proADM) and flow-mediated dilatation (FMD) aiding in the prediction of treatment efficacy. These findings emphasize the potential of a biomarker-driven, multi-faceted approach to managing pediatric POTS.

"Individualized treatment strategies are the future of managing pediatric POTS," says Dr. Junbao Du, the lead researcher. "By understanding the specific mechanisms driving each patient's condition, we can tailor therapies that are not only more effective but also minimize unnecessary interventions. This approach represents a significant step forward in improving the quality of life for children with POTS."

The implications of this review are far-reaching for the clinical management of pediatric POTS. By leveraging biomarkers and other physiological indicators, clinicians can move away from a one-size-fits-all approach and adopt more personalized treatment plans that are likely to yield better results. This could lead to faster symptom relief, fewer hospital visits, and improved long-term outcomes for patients. Furthermore, the study opens the door for future research into additional biomarkers and treatment combinations, potentially revolutionizing the management of POTS and similar conditions in pediatric populations.

###

References

DOI

10.1002/pdi3.2509

Original Source URL

https://doi.org/10.1002/pdi3.2509

Funding information

This manuscript was supported by the National High-Level Hospital Clinical Research Funding (2022CR59).

About Pediatric Discovery

Pediatric Discovery is a Gold Open Access publication and officially sponsored by The National Clinical Research Center for Child Health and Disorders of China, and Children’s Hospital of Chongqing Medical University. The journal does not charge any submission fees. The Article Publication Charge (APC) is currently waived for accepted manuscripts. Pediatric Discovery is an open access and peer-reviewed international journal. The journal aims to advance the health and well-being of infants, children, and adolescents by disseminating cutting-edge discovery and knowledge in the field. It provides a platform for publishing and discussing the most important and state-of-the-art basic, translational and clinical discoveries affecting child and adolescent health and disorders in all aspects of pediatric medicine. Directory of Open Access Journals (DOAJ).

Paper title: Pediatric postural orthostatic tachycardia syndrome: From mechanisms to individualized management
10/03/2025 TranSpread
Regions: North America, United States, Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement